Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
Abstract Background Pyroglutamylation of truncated Aβ peptides, which is catalysed by enzyme glutaminyl cyclase (QC), generates pE-Aβ species with enhanced aggregation propensities and resistance to most amino-peptidases and endo-peptidases. pE-Aβ species have been identified as major constituents o...
Main Authors: | Claire Bridel, Torsten Hoffmann, Antje Meyer, Sisi Durieux, Marleen A. Koel-Simmelink, Matthias Orth, Philip Scheltens, Inge Lues, Charlotte E. Teunissen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-06-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13195-017-0266-6 |
Similar Items
-
Functions of glutaminyl cyclase and its isoform in diseases
by: Liu Yu’e, et al.
Published: (2023-01-01) -
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study
by: Philip Scheltens, et al.
Published: (2018-10-01) -
Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation
by: Maike Hartlage-Rübsamen, et al.
Published: (2018-04-01) -
Tetrahydroimidazo[4,5-<i>c</i>]pyridine-Based Inhibitors of <i>Porphyromonas gingivalis</i> Glutaminyl Cyclase
by: Daniel Ramsbeck, et al.
Published: (2021-11-01) -
Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
by: Dr. Chenshu Xu, et al.
Published: (2021-09-01)